Infliximab therapy in an infant with Netherton syndrome.

Cicek F., Cekic Ş., Kilic S. Ş.

Pediatric dermatology, vol.38, no.3, pp.714-716, 2021 (Peer-Reviewed Journal) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 38 Issue: 3
  • Publication Date: 2021
  • Doi Number: 10.1111/pde.14590
  • Journal Name: Pediatric dermatology
  • Journal Indexes: Science Citation Index Expanded, Scopus, Academic Search Premier, CAB Abstracts, EMBASE, MEDLINE
  • Page Numbers: pp.714-716
  • Keywords: childhood, ichthyosis, &#305, nfliximab, Netherton Syndrome, tumor necrosis factor&#8208, a


We present a patient with Netherton syndrome and severe skin manifestations treated with infliximab. By 6 months of age, the child had intractable pruritus, scaling, dry skin, and generalized eczematous lesions resistant to conventional therapies for atopic dermatitis. Clinical improvement was observed following the third infusion of infliximab, and by 12 months of age, the skin lesions completely resolved. Infliximab is a promising option for the management of skin inflammation in Netherton syndrome, even in infants.